Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Sanofi Pasteur...

    Sanofi Pasteur launches 6-in-1 paediatric vaccine in India

    Written by Noha Published On 2016-11-26T09:52:12+05:30  |  Updated On 26 Nov 2016 9:52 AM IST
    Sanofi Pasteur launches 6-in-1 paediatric vaccine in India

    New Delhi : Sanofi Pasteur announced the launch of paediatric 6-in-1 vaccine, Hexaxim, which provides protection against six major childhood diseases in India.


    The ready to use fully liquid vaccine provides protection against diphtheria, tetanus, pertussis (whooping cough), polio, haemophilus influenza B and hepatitis B, Sanofi Pasteur said in a statement.


    It is indicated for primary and booster vaccination of infants and toddlers from six weeks to 24 months of age, it added.


    Sanofi Pasteur India, Nepal and Sri Lanka Country Head Jean-Pierre Baylet said, "Hexaxim brings to life Sanofi Pasteur's mission to improve human health by developing superior innovative vaccination solutions against infectious diseases."


    "Given the large influx of patients met by pediatricians in India, Hexaxim will offer convenience and ensure consistency in administering the right dose of each antigen every single time," he added.


    Hexaxim, during its clinical study assessment, was found to be safe and well tolerated as a primary series and booster vaccination in all schedules, countries, and ethnicities tested, Sanofi Pasteur said.


    Each dose of Hexaxim takes 24 to 36 months for manufacturing, of which 70 per cent of the time is spent on quality tests, it added.


    Sanofi Pasteur is the vaccines global business unit of pharma major Sanofi.

    diphtheriahaemophilus influenza Bhepatitis BHexaximJean Pierre Bayletmajor childhood diseasespaediatric vaccinepertussispolioSanofitetanus
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Noha
    Noha
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok